PRESS RELEASE
14 December 2023 15:15:00 CET

Egetis' Investor Day on December 19: Agenda and Registration Details

Stockholm, Sweden, December 14, 2023. Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today announced the Agenda and Registration Details for the Company's Investor Day on Tuesday December 19, 2023, in Stockholm, Sweden, for investors, analysts and media.

Time: Tuesday, December 19, 2023, at 3:00 pm - 6:00 pm CET (9:00 am – 12:00 pm ET)
Venue: Redeye, Mäster Samuelsgatan 42, Stockholm, Sweden
Registration (to attend in person): Please register by email to info@egetis.com
Webcast (no preregistration required): Please follow this link
https://www.redeye.se/events/965111/capital-markets-day-egetis-therapeutics-2

During the event, the Company will provide an update and review of its strategy and pipeline prospects. The presentations will focus on the Company's drug candidate *Emcitate* (tiratricol) and the related unmet medical need it will address, development plans, commercial opportunities, and additional activities to create and enhance long-term shareholder value. Presentations will be made by members of Egetis' management team, as well as invited key opinion leaders. Presentations will be held in English. The webcast will also be available on Egetis webpage www.egetis.com after the event.

Agenda

Time (CET)	Subject	Presenter(s)
15:00	Welcome, Corporate strategy and overview	Nicklas Westerholm, CEO
15:15	Development of *Emcitate* for MCT8 deficiency patients	Westerholm
15:30	MCT8 deficiency and the unmet medical need	Dr Andrew Bauer, CHOP, Philadelphia, PA
15:50	Q&A	Bauer & Westerholm
16:00	Global plans for commercializing *Emcitate*	Henrik Krook, VP Commercial
16:15	Understanding MCT8 deficiency patients' & caregivers' needs	Nigel Nicholls, Global Patient Advocacy Director
16:30	Improving disease awareness of MCT8 deficiency	Peter Verwaijen, Global Head of Marketing & Brand Strategy
16:45	US launch preparations for *Emcitate*	Anny Bedard, President Egetis North America

17:00	Q&A	Krook, Nicholls, Verwaijen, Bedard, Westerholm
17:10	Break	
17:30	RTH-beta and the unmet medical need	Dr Carla Moran, University College Dublin
17:50	Q&A	Moran & Westerholm
18:00	Concluding remarks	Nicklas Westerholm, CEO

For further information, please contact:

Nicklas Westerholm, CEO
+46 (0) 733 542 062
nicklas.westerholm@egetis.com

Karl Hård, Head of Investor Relations & Business Development
+46 (0) 733 011 944
karl.hard@egetis.com

About Egetis Therapeutics

Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.
The Company's lead drug candidate *Emcitate* is under development for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. In previous studies (Triac Trial I and a long-term real-life study) *Emcitate* has shown highly significant and clinically relevant results on serum thyroid hormone T3 levels and secondary clinical endpoints. Egetis submitted a marketing authorisation application (MAA) for *Emcitate* to the European Medicines Agency (EMA) in October 2023.
After a dialogue with the FDA, Egetis is conducting a small randomized, placebo-controlled pivotal study in 16 patients to verify the results on T3 levels seen in previous clinical trials and publications. Egetis intends to submit a new drug application (NDA) in the US for *Emcitate* in mid 2024 under the Fast-Track Designation granted by FDA.
Emcitate holds Orphan Drug Designation (ODD) for MCT8 deficiency and resistance to thyroid hormone type beta (RTH-beta) in the US and the EU. MCT8 deficiency and RTH-beta are two distinct indications, with no overlap in patient populations. *Emcitate* has been granted Rare Pediatric Disease Designation (RPDD) which gives Egetis the opportunity to receive a Priority Review Voucher (PRV) in the US, after approval. This voucher can be transferred or sold to another sponsor.
The drug candidate *Aladote* is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) overdose. A proof of principle study has been successfully completed and the design of the upcoming pivotal Phase Iib/III study with the purpose of applying for market approval in the US and Europe for *Aladote* has been finalized after completed interactions with FDA, EMA and MHRA and study start is planned after *Emcitate* submissions have been completed. *Aladote* has been granted ODD in the US and in the EU.
Egetis Therapeutics (STO: EGTX) is listed on the Nasdaq Stockholm main market. For more information, see www.egetis.com

PRESS RELEASE
14 December 2023 15:15:00 CET

Attachments

Egetis' Investor Day on December 19: Agenda and Registration Details